While paradigms shift in von Hippel-Lindau management, questions remain in optimal multidisciplinary neuro-oncology care
Neuro Oncol
.
2023 May 4;25(5):839-840.
doi: 10.1093/neuonc/noad049.
Author
Roy E Strowd
1
Affiliation
1
Departments of Neurology, Internal Medicine, and the Translational Sciences Institute, Comprehensive Cancer Center, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC 27157.
PMID:
36869778
PMCID:
PMC10158106
DOI:
10.1093/neuonc/noad049
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
von Hippel-Lindau Disease* / complications
von Hippel-Lindau Disease* / therapy
Substances
belzutifan